Stockscreener 앱 받기
4.73
3.96%
0.18
시간 외 거래:
4.75
0.02
+0.42%
전일 마감가:
$4.55
열려 있는:
$4.6
하루 거래량:
820.39K
Relative Volume:
0.67
시가총액:
$687.70M
수익:
$28.94M
순이익/손실:
$-54.29M
주가수익비율:
-10.18
EPS:
-0.4647
순현금흐름:
$-26.02M
1주 성능:
+1.50%
1개월 성능:
+8.74%
6개월 성능:
+219.59%
1년 성능:
+176.61%
1일 변동 폭
$4.5306
$4.755
1주일 범위
$4.5301
$4.915
52주 변동 폭
$1.30
$5.43
Omniab Inc Stock (OABI) Company Profile
명칭
Omniab Inc
전화
510-250-7800
주소
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
4.73 | 687.70M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-21 | 개시 | The Benchmark Company | Buy |
| 2023-04-13 | 개시 | Craig Hallum | Buy |
| 2023-02-22 | 개시 | Cowen | Outperform |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-11-29 | 개시 | SVB Leerink | Outperform |
| 2022-11-28 | 개시 | Stifel | Buy |
모두보기
Omniab Inc 주식(OABI)의 최신 뉴스
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy - Zacks Investment Research
OmniAb, Inc.Common Stock (Nasdaq:OABI) Detailed Stock Data - The Chronicle-Journal
OmniAb Inc. OABI Stock Holds Support As Traders Weigh Weak Margins - StocksToTrade
OmniAb Inc. Stock Holds Range As Traders Weigh Deep Losses Against Strong Balance Sheet - timothysykes.com
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
OmniAb Company Profile & Introduction - Moomoo
OmniAb Company Profile & Introduction - Moomoo
OABI Looks 50.3% Overvalued on GF Value™ - GuruFocus
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - finance.yahoo.com
OmniAb to Participate in Upcoming Investor Conferences - Yahoo Finance
OmniAb (OABI) Earnings Reading: EPS Beats Its Estimate at the Close; Post-Earnings: The Share Price Adds 8.78%EPS Surprise History - vinanet.vn
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseEarnings Stability Report - vinanet.vn
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseUpward Estimate Revision - dars.gov.et
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the CloseBanking Earnings Report - vinanet.vn
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the ClosePositive Surprise Momentum - siam.in
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
OmniAb boosts 2026 cash guidance after milestone-rich Eli Lilly deal validates its biotech platform. - Pluang
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Neurocrine (NBIX) and Evaxion Biotech (EVAX) - The Globe and Mail
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
OmniAb Company Profile & Introduction - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - TradingView
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - GuruFocus
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging - finance.biggo.com
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00 - GuruFocus
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m - AllSci
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
$OmniAb (OABI.US)$ - Moomoo
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com South Africa
Why is OmniAb stock surging today? By Investing.com - Investing.com Nigeria
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OABI Looks 15.8% Overvalued on GF Value™ - GuruFocus
Why is OmniAb stock surging today? - Investing.com
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com India
Why is OmniAb stock surging today? By Investing.com - Investing.com Canada
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
Why is OmniAb stock surging today? By Investing.com - Investing.com UK
Why is OmniAb stock surging today? - Investing.com
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb raises 2026 cash guidance on licensing activity By Investing.com - Investing.com Canada
Omniab Inc (OABI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Omniab Inc 주식 (OABI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
| FOEHR MATTHEW W | Officer |
Apr 07 '26 |
Proposed Sale |
1.49 |
19,244 |
28,577 |
0 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
268,396 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '26 |
Sale |
1.49 |
6,913 |
10,300 |
261,483 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
406,242 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '26 |
Sale |
1.49 |
7,157 |
10,664 |
399,085 |
| Berkman Charles S | Officer |
Apr 07 '26 |
Proposed Sale |
1.49 |
7,157 |
10,628 |
0 |
| Berkman Charles S | Chief Legal Officer |
Feb 18 '26 |
Option Exercise |
0.00 |
18,750 |
0 |
402,373 |
| Berkman Charles S | Chief Legal Officer |
Feb 18 '26 |
Sale |
1.71 |
9,673 |
16,541 |
392,700 |
0.43%
자본화:
|
볼륨(24시간):